SCHEMBL1815009

SCHEMBL1815009

CCCCCCCC(=O)NC(Cc1ccccc1)C(=O)O

nearest known ligand 0.81

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.81
ITGB3 P05106 2/20 0.65
ITGA2B P08514 2/20 0.65
PSMB5 P28074 2/20 0.64
HDAC3 O15379 1/20 0.60
HDAC4 P56524 1/20 0.60
HDAC1 Q13547 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC2 Q92769 1/20 0.60
HDAC10 Q969S8 1/20 0.60
HDAC11 Q96DB2 1/20 0.60
HDAC8 Q9BY41 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
HDAC9 Q9UKV0 1/20 0.60
HDAC5 Q9UQL6 1/20 0.60
NOD1 Q9Y239 1/20 0.58
EPHX2 P34913 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4066786 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL9506671 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL9716823 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL1815011 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL9666114 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL22494096 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL22494095 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL21998924 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL22494097 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL15285319 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2025-01-02 US claimed
EP-4433093-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-09-25 EP claimed
EP-4299057-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-01-03 EP claimed
WO-2023084118-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2023-05-19 WO claimed
EP-4180060-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2023-05-17 EP claimed
US-20250387340-A1 COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2025-12-25 US disclosed
CN-119486752-A Compositions comprising peptides or proteins and acylated amino acids 阿道恰公司 2025-02-18 CN disclosed
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2025-01-02 US disclosed
EP-4433093-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-09-25 EP disclosed
CN-118488855-A Solid composition comprising peptide or protein and acylated amino acid 阿道恰公司 2024-08-13 CN disclosed
WO-2024003400-A1 COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2024-01-04 WO disclosed
EP-4299071-A1 COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-01-03 EP disclosed
EP-2501389-A1 POLYSACCHARIDE / BMP COMPLEXES WHICH ARE SOLUBLE AT PHYSIOLOGICAL PH Adocia (FR) 2012-09-26 EP disclosed
US-20110178011-A1 Polysaccharide/BMP complexes which are soluble at physiological pH ADOCIA (FR) 2011-07-21 US disclosed
US-20110172166-A1 Anionic polysaccharides functionalized by a hydrophobic acid derivative ADOCIA (FR) 2011-07-14 US disclosed
WO-2011077405-A1 ANIONIC POLYSACCHARIDES FUNCTIONALISED BY A HYDROPHOBIC ACID DERIVATIVE ADOCIA (FR) 2011-06-30 WO disclosed
WO-2011061615-A1 POLYSACCHARIDE / BMP COMPLEXES WHICH ARE SOLUBLE AT PHYSIOLOGICAL PH ADOCIA (FR) 2011-05-26 WO disclosed
EP-0178911-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1992-01-22 EP disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US disclosed
EP-0178911-A2 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1986-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172166-A1 Anionic polysaccharides functionalized by a hydrophobic acid derivative ALG1, CD44, FUT6 FAAH 3193/4885ITGB3 324/4885ITGA2B 453/4885
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID NPPA, BCAT1, ANPEP FAAH 858/4885ITGB3 4058/4885ITGA2B 3499/4885
US-20250387340-A1 COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID NPR1, NPPA, SLC7A1 FAAH 399/4885ITGB3 2164/4885ITGA2B 2090/4885
US-20110178011-A1 Polysaccharide/BMP complexes which are soluble at physiological pH BMP1, BMP2, BMP6 FAAH 4615/4885ITGB3 1719/4885ITGA2B 2161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.